Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Coloplast A/S    COLO B   DK0060448595

COLOPLAST A/S

(COLO B)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
02/17/2020 02/18/2020 02/19/2020 02/20/2020 02/21/2020 Date
954(c) 980(c) 991.4(c) 980(c) 960.2(c) Last
141 067 285 397 342 115 304 324 279 614 Volume
+0.55% +2.73% +1.16% -1.15% -2.02% Change
More quotes
Financials (DKK)
Sales 2020 19 454 M
EBIT 2020 6 106 M
Net income 2020 4 601 M
Debt 2020 404 M
Yield 2020 1,94%
Sales 2021 20 938 M
EBIT 2021 6 632 M
Net income 2021 5 096 M
Debt 2021 162 M
Yield 2021 2,14%
P/E ratio 2020 44,4x
P/E ratio 2021 40,1x
EV / Sales2020 10,5x
EV / Sales2021 9,75x
Capitalization 204 B
More Financials
Company
Coloplast A/S specializes in the design, manufacturing, and marketing of disposable medical products. Net sales break down by family of products as follows: - hygiene products (49.1%): urine bags, plugs, urinary testing systems and sets, etc.; - ostomy care products (39.9%): bags and equipment... 
More about the company
Surperformance© ratings of Coloplast A/S
Trading Rating : Investor Rating :
More Ratings
Latest news on COLOPLAST A/S
02/21COLOPLAST A/S : - Announcement no. 2/2020 - Share Buyback Programme
AQ
02/10COLOPLAST A/S : Trading in Coloplast shares by board members, executives or asso..
PU
02/07COLOPLAST A/S : - Trading in Coloplast shares by board members, executives or as..
AQ
02/06COLOPLAST A/S : delivers solid start to the year with 8% organic growth
AQ
02/06COLOPLAST A/S : - Announcement no. 01/2020 – Interim Financial Report, Q1 ..
AQ
02/06COLOPLAST A/S : 1st quarter results
CO
02/03COLOPLAST A/S : quaterly earnings release
01/20COLOPLAST A/S : - Allocation of Share Options
AQ
01/07Coloplast awarded Enterostomal Therapy products agreement with Premier Inc.
GL
2019COLOPLAST A/S : Trading in Coloplast shares by board members, executives or asso..
PU
2019COLOPLAST A/S : Security operations
CO
2019COLOPLAST A/S : - Trading in Coloplast shares by board members, executives or as..
AQ
2019COLOPLAST : Ex-dividend day for final dividend
FA
2019COLOPLAST : Announcement no. 14/2019 - Articles of Association
AQ
2019COLOPLAST : Announcement no. 13/2019 Decisions of Annual General Meeting 2019
AQ
More news
News in other languages on COLOPLAST A/S
02/03COLOPLAST A/S : publication des résultats trimestriels
02/03COLOPLAST A/S : Veröffentlichung des Quartalsergebnisses
2019COLOPLAST : Ex-dividend day for final dividend
2019STOCK MARKET PARIS : Le CAC40 à 3% des 6000 points
2019EN DIRECT DES MARCHES : ArcelorMittal, Safran, Casino, Ipsen, Rubis, Teleperf..
More news
Analyst Recommendations on COLOPLAST A/S
More recommendations
Sector news : Medical Supplies
02/21Pharmaceutical companies develop system to better track counterfeit drugs
RE
02/20FISHER & PAYKEL HEALTHCARE : F&P Healthcare Raises Fiscal Year Earnings, Revenue..
DJ
02/20SMITH & NEPHEW : +Nephew forecasts sales growth after best year since 2010
RE
02/18MEDTRONIC : Raises 2020 Guidance, Sets 4Q Outlook
DJ
02/18MEDTRONIC : 3Q Profit, Sales Rise
DJ
More sector news : Medical Supplies
Chart COLOPLAST A/S
Duration : Period :
Coloplast A/S Technical Analysis Chart | COLO B | DK0060448595 | MarketScreener
Technical analysis trends COLOPLAST A/S
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 19
Average target price 777,56  DKK
Last Close Price 960,20  DKK
Spread / Highest target 3,10%
Spread / Average Target -19,0%
Spread / Lowest Target -49,0%
EPS Revisions
Managers
NameTitle
Kristian Villumsen President & Chief Executive Officer
Lars Søren Rasmussen Chairman
Allan Rasmussen Executive Vice President-Global Operations
Anders Lonning-Skovgaard Chief Financial Officer & Executive Vice President
Oliver Johansen Senior VP-Global Research & Development
Sector and Competitors